Seeking Alpha

badsangria

badsangria
Send Message
View as an RSS Feed
View badsangria's Comments BY TICKER:
Latest  |  Highest rated
  • Sarepta Therapeutics: A Bigger Cake Outweighs A Lower Chance For A Party [View article]
    So Prosena investors knew a binary event was coming - in October. Only it came in September.

    Sarepta investors knew a binary event was coming, and they thought it was coming in late August or September. It came on July 24th.

    It's dangerous to assume you have the timing down, and even more dangerous to assume there will be no surprises and that the stock will continue a headlong advance to 70. Sarepta has had more head fakes than the medusa.
    Sep 24 08:31 AM | Likes Like |Link to Comment
  • Sarepta Therapeutics: A Bigger Cake Outweighs A Lower Chance For A Party [View article]
    "You can always get out before..."; I'm sure there are plenty of Prosena investors who thought that, too.
    Sep 23 05:06 PM | Likes Like |Link to Comment
  • JAKKS Pacific: Is There Any Value At These Levels? [View article]
    A timely take from Forbes:

    http://onforb.es/17qocj4
    Aug 31 10:44 AM | 1 Like Like |Link to Comment
  • When Others Are Fearful, Be Greedy [View article]
    I am greedy and fearful every trading day, sometimes at the same time.
    Aug 15 06:05 PM | 2 Likes Like |Link to Comment
  • Update To My 50 Predictions For 2013 [View article]
    Great article, Ploutos.

    I don't know what your final "GPA" was but, really, it doesn't matter because these predictions are not equal in value. Nailing the S&P 500, Russell 2000 and VIX alone were huge calls, compared, say, to a Fortune 500 ceo sex scandal. I just added you to my "people to pay attention to" list.

    Thanks much.
    Aug 4 12:06 PM | 3 Likes Like |Link to Comment
  • Skullcandy: Not Dead Yet [View article]
    I have a picture of a flaming skull above my monitor as a reminder that the earnings report isn't over until the conference call is finished, prompted by SKUL's March 7th performance. No thanks.
    Aug 3 03:26 AM | Likes Like |Link to Comment
  • JAKKS Pacific: Down 40% But Still Too Expensive [View article]
    Let the smoke clear, buy some shares, see what happens. Or don't. But forget trying to apply conventional valuation here because it is very clear this company is a dog at present.
    Jul 28 07:25 PM | Likes Like |Link to Comment
  • JAKKS Pacific: Down 40% But Still Too Expensive [View article]
    He bought a little under 1.4 million shares for $7.41/sh the day it tanked. Not too worried about catching a falling knife, but then, his net worth is more than $7 billion.

    It should also be noted that he has a start-up company developing tech for JAKK products. So the relationship goes beyond his friendship with Mr. Berman.
    Jul 25 11:54 PM | Likes Like |Link to Comment
  • Realize Gains Before This Bull Dies [View article]
    Your article is feeding my confirmation bias big time, Raven. I have moved largely to cash and have started positions in several short ETFs this week. Thanks
    Jul 25 04:37 PM | 4 Likes Like |Link to Comment
  • Sarepta Traders Brace For Possible Accelerated Approval For Eteplirsen [View article]
    Buy RNA
    Jul 25 04:07 PM | Likes Like |Link to Comment
  • Apple (AAPL) has bought transportation app developer HopStop, Bloomberg reports. HopStop's data and navigation tools for local transportation options such as buses, trains, taxi services, and bike paths would help address user complaints about Apple Maps' dearth of public transit data/features relative to Google Maps. The report comes shortly after Apple confirmed it bought Canadian location database developer Locationary. Update: Apple confirms it has bought HopStop. [View news story]
    Well, gee, if you are that disgusted why don't you sell them all?
    Jul 19 06:01 PM | 8 Likes Like |Link to Comment
  • Sarepta Traders Brace For Possible Accelerated Approval For Eteplirsen [View article]
    At the JPM Healthcare Conference this morning, SRPT ceo Chris Garabedian said the following:

    "And we believe under the guidelines particularly under accelerated approval, we're a surrogate market in this case dystrophin seems to be reasonably predicting the clinical response we're seeing here. It would be sufficient to be acceptable for a filing and that's something we hope we will find out in the next month or two and be able to communicate our intention of whether or not we'll file on this application for approval."

    Brain, on what basis do you believe a decision will be made before the end of the month?
    Jul 10 09:20 PM | Likes Like |Link to Comment
  • James Altucher: Why The Stock Market Is A Sucker's Game Right Now (And What Stocks I Own) [View article]
    I'm cool with that. It's the writers who say "I have no position in this stock" who raise my eyebrows.
    Jun 30 01:02 PM | 2 Likes Like |Link to Comment
  • Undervalued Stock Of The Week: Himax Technologies [View article]
    What a difference a day makes. Evidently people like the idea of a 4-5% dividend on top of an undervalued growth stock. Big ups to author Brad.
    Jun 26 11:40 AM | Likes Like |Link to Comment
  • Apple Shares Are In The Reign Of Uncertainty [View article]
    Investing and trading are not mutually exclusive.
    Jun 23 09:59 PM | Likes Like |Link to Comment
COMMENTS STATS
129 Comments
159 Likes